ArticleCancer control : journal of the Moffitt Cancer Center
Real-World Comparison of Abiraterone Acetate Versus Docetaxel in Combination With Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Cohort Study From Vietnam.
Article in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IntroductionThe optimal choice between docetaxel and abiraterone in combination with androgen deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC) remains uncertain due to the lack of direct randomized trials. Real-world data, particularly from developing countries, are limited. This study aimed to compare the effectiveness of docetaxel versus abiraterone in combination with ADT and to identify prognostic factors associated with survival outcomes in a Vietnamese population.MethodsWe conducted a retrospective cohort study of patients with mHSPC treated at Vietnam National Cancer Hospital between January 2021 and December 2025. Eligible patients received first-line ADT combined with either docetaxel or abiraterone acetate. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method and compared using the log-rank test. Cox proportional hazards models were applied to evaluate prognostic factors.ResultsBaseline characteristics were generally comparable. Abiraterone was associated with a higher rate of deep prostate-specific antigen (PSA) response at 6 months (PSA≤0.2 ng/mL: 43.7% vs. 16.7%, p=0.002). After a median follow-up of 28.6 months, the median OS was 41.4 months in the docetaxel group and 44.6 months in the abiraterone group. Median PFS was 23.6 and 29.6 months, respectively, with no statistically significant differences between groups. In multivariable analysis, baseline PSA>100 ng/mL (HR 1.98, p=0.01, 95% CI: 1.15-3.42) and PSA>0.2 ng/mL at 6 months (HR 3.93, p<0.001, 95% CI: 1.82-8.49) were independent predictors of worse PFS. PSA>0.2 ng/mL at 6 months was also associated with inferior OS (HR 2.66, p=0.03, 95% CI: 1.09-6.47).ConclusionIn this real-world Vietnamese cohort, docetaxel and abiraterone combined with ADT provided comparable survival outcomes in mHSPC. Although abiraterone achieved deeper PSA responses, this did not translate into a survival advantage. Baseline PSA and 6-month PSA response were strong prognostic factors, underscoring the clinical value of PSA kinetics in risk stratification and treatment monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.